Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9561916rdf:typepubmed:Citationlld:pubmed
pubmed-article:9561916lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:9561916lifeskim:mentionsumls-concept:C0022688lld:lifeskim
pubmed-article:9561916lifeskim:mentionsumls-concept:C0016320lld:lifeskim
pubmed-article:9561916lifeskim:mentionsumls-concept:C1510438lld:lifeskim
pubmed-article:9561916lifeskim:mentionsumls-concept:C0182400lld:lifeskim
pubmed-article:9561916pubmed:issue1-2lld:pubmed
pubmed-article:9561916pubmed:dateCreated1998-6-4lld:pubmed
pubmed-article:9561916pubmed:abstractTextA non-radioisotopic method for assessment of human natural killer (NK) cell activity in peripheral blood mononuclear cells (PBMC) was established by labelling K562 erythroleukemia target cells with a fluorescent dye, rhodamine-123 (Rh-123). The labelling and assay conditions were determined for minimizing spontaneous release (SR). In order to investigate whether NK activity assessed by measuring Rh-123 release agrees with the activity determined by a 51Cr release assay, the NK activity of PBMC was measured simultaneously by both assay methods. Statistical analysis demonstrates that NK activities determined by Rh-123 release correlate well with those measured by 51Cr release. The Rh-123 release assay under the conditions determined was found to be applicable to measurement of the enhanced NK activity resulting from pretreatment of effector leukocytes with interferon-alpha. It is concluded that the Rh-123 release assay with use of K-562 labelled target cells is practical for the assessment of human NK activity in laboratories where use of radioisotopes is not permitted or undesirable.lld:pubmed
pubmed-article:9561916pubmed:languageenglld:pubmed
pubmed-article:9561916pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9561916pubmed:citationSubsetIMlld:pubmed
pubmed-article:9561916pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9561916pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9561916pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9561916pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9561916pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9561916pubmed:statusMEDLINElld:pubmed
pubmed-article:9561916pubmed:issn0882-0139lld:pubmed
pubmed-article:9561916pubmed:authorpubmed-author:MuraokaSSlld:pubmed
pubmed-article:9561916pubmed:authorpubmed-author:LievW AWAlld:pubmed
pubmed-article:9561916pubmed:authorpubmed-author:IwaoMMlld:pubmed
pubmed-article:9561916pubmed:authorpubmed-author:KuraneIIlld:pubmed
pubmed-article:9561916pubmed:issnTypePrintlld:pubmed
pubmed-article:9561916pubmed:volume27lld:pubmed
pubmed-article:9561916pubmed:ownerNLMlld:pubmed
pubmed-article:9561916pubmed:authorsCompleteYlld:pubmed
pubmed-article:9561916pubmed:pagination31-45lld:pubmed
pubmed-article:9561916pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:9561916pubmed:meshHeadingpubmed-meshheading:9561916-...lld:pubmed
pubmed-article:9561916pubmed:meshHeadingpubmed-meshheading:9561916-...lld:pubmed
pubmed-article:9561916pubmed:meshHeadingpubmed-meshheading:9561916-...lld:pubmed
pubmed-article:9561916pubmed:meshHeadingpubmed-meshheading:9561916-...lld:pubmed
pubmed-article:9561916pubmed:meshHeadingpubmed-meshheading:9561916-...lld:pubmed
pubmed-article:9561916pubmed:meshHeadingpubmed-meshheading:9561916-...lld:pubmed
pubmed-article:9561916pubmed:meshHeadingpubmed-meshheading:9561916-...lld:pubmed
pubmed-article:9561916pubmed:meshHeadingpubmed-meshheading:9561916-...lld:pubmed
pubmed-article:9561916pubmed:meshHeadingpubmed-meshheading:9561916-...lld:pubmed
pubmed-article:9561916pubmed:meshHeadingpubmed-meshheading:9561916-...lld:pubmed
pubmed-article:9561916pubmed:meshHeadingpubmed-meshheading:9561916-...lld:pubmed
pubmed-article:9561916pubmed:articleTitleA non-radioisotopic human natural killer cell assay using rhodamine-123 fluorescent dye as labelling probe.lld:pubmed
pubmed-article:9561916pubmed:affiliationFujimoto Pharmaceutical Corporation, Osaka, Japan.lld:pubmed
pubmed-article:9561916pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9561916lld:pubmed